Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data

Objective: Ustekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti- tumour necrosis factor α drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiveness and safety of ustekinumab...

Full description

Bibliographic Details
Published in:	Farmacia Hospitalaria
Main Authors:	Manuel David Gil-Sierra, Esmeralda Ríos-Sánchez, María del Pilar Briceño-Casado
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Subjects:	ustekinumab psoriasis retrospective studies treatment outcome drug evaluation studies
Online Access:	http://www.aulamedica.es/fh/pdf/11420.pdf

Similar Items

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01)

Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
by: Melis Gönülal, et al.
Published: (2023-12-01)

Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis
by: Karine Rodríguez-Fernández, et al.
Published: (2024-10-01)

Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
by: I. V. Rychkova, et al.
Published: (2019-08-01)

Persistence and Adherence to Biologics in Patients with Psoriasis in Taiwan: A New Biologics User Cohort Study
by: Yu-Huei Huang, et al.
Published: (2022-05-01)

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)

Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice
by: Cristina Galache Osuna, et al.
Published: (2020-10-01)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
by: Seung-Won Jung, et al.
Published: (2022-05-01)

Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report
by: Andrei Ovidiu Olteanu, et al.
Published: (2024-01-01)

Ustekinumab Efficacy in Children with Palmoplantar Psoriasis: Case Series
by: Maria A. Leonova, et al.
Published: (2024-11-01)

Ustekinumab is effective in the treatment of linear psoriasis: a case report and literature review
by: Jinxu Qi, et al.
Published: (2025-04-01)

Effectiveness of resuming ustekinumab therapy in psoriasis patients with metabolic disorders. Clinical experience
by: I. V. Rychkova, et al.
Published: (2019-02-01)

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
by: Rosita Saraceno, et al.
Published: (2013-09-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
by: Steven R. Feldman, et al.
Published: (2024-12-01)

Ustekinumab is effective and safe in the long‐term treatment of erythrodermic psoriasis: Multicenter study in daily practice
by: Clara Plana, et al.
Published: (2024-06-01)

Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients
by: Xingyu Li, et al.
Published: (2024-12-01)

Ustekinumab Demonstrates Lower Uveitis Risk in Moderate to Severe Psoriasis Patients Compared with Tumor Necrosis Factor-α Inhibitors
by: Chul Hwan Bang, et al.
Published: (2024-09-01)

Ustekinumab in the Treatment of Generalized Pustular Psoriasis in a Pregnant Patient
by: Wu H, et al.
Published: (2024-05-01)

RESULTS OF USTEKINUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO THE DATA OF PSUMMIT 1 AND PSUMMIT 2
by: Yu. L. Korsakova, et al.
Published: (2015-04-01)

Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis)
by: P. A. Makarchuk, et al.
Published: (2020-10-01)

Paradoxical granulomatous reaction to ustekinumab
by: Chinemelum Obijiofor, et al.
Published: (2024-09-01)

Impact of Treatment with Ustekinumab on Severe Infections in a Patient with Uncontrolled Psoriasis and Late-Onset Combined Primary Immunodeficiency: Case Report
by: Luiz Euribel Prestes-Carneiro, et al.
Published: (2023-09-01)

Ankilozan Spondilit, Crohn Hastalığı ve Anti-tümör Nekroz Faktör-alfa Tedavi ile İndüklenen Psoriasis olan Hastada Ustekinumab Tedavisine Dramatik Yanıt
by: Sevilay Kılıç, et al.
Published: (2020-12-01)

Ustekinumab Biosimilars
by: Elena Carmona-Rocha, et al.
Published: (2024-11-01)

The cost of biologics for psoriasis is increasing
by: Judy Cheng, et al.
Published: (2014-12-01)

Treatment efficacy and patient satisfaction of ustekinumab compared with tumor necrosis factor-alpha inhibitors in Chinese patients with moderate-to-severe psoriasis: a real-world study
by: Bin Guo, et al.
Published: (2024-12-01)

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

A case of ustekinumab-induced pustular psoriasis was treated with IL-17A inhibitor
by: LIN Junjie, et al.
Published: (2024-11-01)

Successful Treatment of Ustekinumab-Associated Lichenoid Drug Eruption with Upadacitinib: A Case Report
by: Xia M, et al.
Published: (2025-04-01)

Characteristics of patients with psoriatic arthritis treated with ustekinumab. Evidence from real-life clinical practice
by: Yu. L. Korsakova, et al.
Published: (2021-01-01)

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
by: Selma Atalay, et al.
Published: (2022-07-01)

Adalimumab induced psoriasis in Crohn’s disease and treatment with ustekinumab: case report and special histopathological findings
by: Fang Qiu, et al.
Published: (2025-01-01)

The Effects of the Biological Agents Infliximab, Vedolizumab, and Ustekinumab on Intestinal Anastomosis: An Experimental Study in Rats
by: Alexandra Menni, et al.
Published: (2025-04-01)

Blood cytokines as potential predictors of therapy effectiveness in patients with moderate to severe psoriasis treated with the IL-12/IL-23 inhibitor ustekinumab
by: Arfenya E. Karamova, et al.
Published: (2025-03-01)

Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study
by: Hao Trong Nguyen, et al.
Published: (2023-11-01)

Comparative Efficacy and Safety of Ustekinumab and Secukinumab in the Treatment of Generalized Pustular Psoriasis: A 48-Week Retrospective Cohort Study with Genetic Background Analysis
by: Ruan SF, et al.
Published: (2024-09-01)

Unmet need for and impact of adopting immunobiological drugs for moderate to severe plaque psoriasis in a pediatric population
by: Ana Clara Maia Palhano, et al.
Published: (2024-06-01)

Secukinumab-induced paradoxical palmoplantar pustular psoriasis
by: Yıldız Gürsel Ürün, et al.
Published: (2022-12-01)

Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study
by: Lu W, et al.
Published: (2024-06-01)